Ferreira Julio Cesar Batista, Mochly-Rosen Daria, Boutjdir Mohamed
Stanford University, School of Medicine, Stanford, CA, USA.
Front Biosci (Schol Ed). 2012 Jan 1;4(2):532-46. doi: 10.2741/s283.
Cardiac excitability and electrical activity are determined by the sum of individual ion channels, gap junctions and exchanger activities. Electrophysiological remodeling during heart disease involves changes in membrane properties of cardiomyocytes and is related to higher prevalence of arrhythmia-associated morbidity and mortality. Pharmacological and genetic manipulation of cardiac cells as well as animal models of cardiovascular diseases are used to identity changes in electrophysiological properties and the molecular mechanisms associated with the disease. Protein kinase C (PKC) and several other kinases play a pivotal role in cardiac electrophysiological remodeling. Therefore, identifying specific therapies that regulate these kinases is the main focus of current research. PKC, a family of serine/threonine kinases, has been implicated as potential signaling nodes associated with biochemical and biophysical stress in cardiovascular diseases. In this review, we describe the role of PKC isozymes that are involved in cardiac excitability and discuss both genetic and pharmacological tools that were used, their attributes and limitations. Selective and effective pharmacological interventions to normalize cardiac electrical activities and correct cardiac arrhythmias will be of great clinical benefit.
心脏的兴奋性和电活动由单个离子通道、缝隙连接和离子交换器活动的总和决定。心脏病期间的电生理重塑涉及心肌细胞膜特性的改变,并且与心律失常相关的发病率和死亡率的较高发生率有关。对心脏细胞进行药理和基因操作以及心血管疾病的动物模型被用于识别电生理特性的变化以及与该疾病相关的分子机制。蛋白激酶C(PKC)和其他几种激酶在心脏电生理重塑中起关键作用。因此,确定调节这些激酶的特定疗法是当前研究的主要重点。PKC是丝氨酸/苏氨酸激酶家族,被认为是与心血管疾病中的生化和生物物理应激相关的潜在信号节点。在本综述中,我们描述了参与心脏兴奋性的PKC同工酶的作用,并讨论了所使用的遗传和药理工具、它们的特性和局限性。使心脏电活动正常化并纠正心律失常的选择性和有效药理干预将具有巨大的临床益处。